| name | Polycaprolactone (PCL) Fillers |
| Classification | Biocompatible synthetic polymer filler for aesthetic procedures (e.g., facial augmentation). |
| Pharmacokinetics | PCL is a biocompatible material. It is gradually absorbed by the body over a period of months or years, depending on the volume and depth of injection. The degradation process is not fully understood, but it involves hydrolysis and other biochemical pathways. There are no specific pharmacokinetic studies directly on PCL fillers for this use, but data from other similar biomaterials is used for general understanding of degradation and distribution. |
| suggested dosage | Dosage is highly variable and dependent on the specific filler product, the area of treatment, and the desired aesthetic outcome. This is determined by a qualified physician, and should not be self-administered. It is crucial to follow the specific product guidelines and instructions. |
| indications | Used to augment facial features, such as cheeks, lips, and other areas needing volume. Often used for correcting wrinkles and improving facial contours. |
| Safety in pregnancy | PCL filler safety during pregnancy is not well-established. As with all medical procedures during pregnancy, potential risks and benefits should be carefully weighed with a doctor. There is no conclusive evidence to indicate PCL is harmful or beneficial during pregnancy. There is a lack of long-term data. |
| Safety in breastfeeding | Data is very limited on the safety of PCL fillers during breastfeeding. It's best to avoid using PCL fillers during this time. The possibility of filler material entering the bloodstream and being transferred to the infant via breast milk is a concern, although it's unlikely, but there is no established consensus. |
| side effects | | 1 | Pain, swelling, bruising, redness, or itching at the injection site. | | 2 | Infection (rare). | | 3 | Changes in skin texture or appearance. | | 4 | Granuloma formation (a local reaction in which the body forms a mass of immune cells around the filler). | | 5 | Migration of the filler (filler moving from the initial injection site). | | 6 | Allergic reactions (possible, but rare). | | 7 | Asymmetry in treated areas. |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity or allergy to PCL or other components of the filler. | | 2 | Active infection at the injection site. | | 3 | Uncontrolled bleeding disorders. | | 4 | Conditions that might compromise healing or increase risk of infection. | | 5 | Pre-existing skin conditions in the targeted area. |
|
| interactions | Limited data available. No known significant drug interactions, but concurrent use of other medications that affect blood clotting or immune function should be discussed with the physician. |
| warnings | | 1 | Filler placement needs to be precisely managed. | | 2 | Serious complications from misuse, improper injection technique, or inadequate assessment of the patient are possible. | | 3 | Proper physician consultation and informed consent are essential. |
|
| precautions | | 1 | Careful consideration of the patient's medical history and overall health. | | 2 | Selection of a qualified and experienced physician. | | 3 | Potential for incomplete or uneven results. | | 4 | Possible necessity of further treatment or correction due to the degradation of the filler over time. |
|
| additional informations | | 1 | The longevity of the effect varies significantly based on the individual, the product used, and the treatment area. Multiple treatments may be required. | | 2 | Proper aftercare instructions should be followed diligently to minimize risks. |
|
| patient specific info | |
